UNH·UnitedHealth Group Incorporated

UnitedHealth Group is a major player in the U.S. and international healthcare sector, operating as a diversified enterprise with distinct segments including UnitedHealthcare for health benefit plans, Optum Health for care delivery, Optum Insight for data analytics, and Optum Rx for pharmacy services. This integrated model allows the company to address a broad spectrum of healthcare needs across various customer bases and stakeholders. In its most recent reported quarters, UnitedHealth Group demonstrated mixed performance against analyst expectations. For Q1 2026, the company reported an Earnings Per Share (EPS) of $7.23, significantly beating the estimated $6.60, and revenue of $111.72 billion, surpassing the estimate of $109.65 billion. This followed a Q4 2025 where actual EPS of $2.11 missed the estimate of $2.12, and revenue of $113.22 billion fell short of the $114.96 billion estimate. Looking at the prior two quarters, Q3 2025 saw actual EPS of $2.92 beat the estimate of $2.81, with revenue not estimated, and Q2 2025 reported actual EPS of $4.08 missing the estimate of $4.45, with revenue also not estimated. Historically, UnitedHealth Group has shown a pattern of revenue growth, with reported revenues generally increasing year-over-year, though EPS performance against estimates has been inconsistent, with beats and misses occurring across recent periods. The company has experienced a beat in EPS in 3 of the last 5 reported quarters. Recent news highlights UnitedHealth Group's appeal to hedge funds, with Mizuho and UBS raising price targets to $440 and $460 respectively, citing strong Q1 earnings and reduced managed care risk. However, a Congressional report estimating significant Medicare Advantage overpayments, with UNH as a primary beneficiary, introduces regulatory scrutiny. Investors will be watching for continued execution on operational performance, management of managed care risks, and the potential impact of regulatory developments on future earnings.